What's Going On With Tharimmune Shares Monday?
What's Going On With Tharimmune Shares Monday?
"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities," said Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.
Tharimmune, Inc.（納斯達克股票代碼：THAR）股價週一最初上漲，但在該公司在美國肝病研究協會（AASLD）第75次會議上公佈臨床數據後，股價出現逆轉。以下是你需要知道的。
What To Know: Tharimmune, a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented positive clinical data from a Phase I trial of TH104, a potential treatment for chronic pruritus in chronic liver disease.
須知：Tharimmune是一家處於臨床階段的生物技術公司，正在開發炎症和免疫學候選治療產品組合，該公司提供了來自慢性肝病慢性瘙癢症潛在治療方法 TH104 的I期試驗的積極臨床數據。
The clinical data showed that higher levels of TH104 in the blood were associated with a reduction in itching, a common symptom of chronic pruritus. The treatment also appeared safe, with no serious side effects reported.
臨床數據顯示，血液中 TH104 水平升高與瘙癢減少有關，瘙癢是慢性瘙癢的常見症狀。該治療似乎也很安全，沒有報告嚴重的副作用。
"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities," said Randy Milby, CEO of Tharimmune.
「我們期待在未來幾個月內啓動2期多劑量遞增劑量試驗，以評估原發性膽源性膽管炎（PBC）患者慢性瘙癢症的 TH104，預計將在 2025 年公佈一線數據。同時，我們將繼續與美國和歐盟監管機構接觸。」 Tharimmune首席執行官蘭迪·米爾比說。
How To Buy THAR Shares
如何購買 THAR 股票
By now you're likely curious about how to participate in the market for Tharimmune – be it to purchase shares, or even attempt to bet against the company.
到目前爲止，你可能對如何參與Tharimmune的市場感到好奇——無論是購買股票，還是試圖對該公司下注。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share.
購買股票通常通過經紀帳戶完成。您可以在此處找到可能的交易平台列表。許多股票允許您購買 「部分股票」，這使您無需購買整股即可擁有部分股票。
In the case of Tharimmune, which is trading at $1.93 as of publishing time, $100 would buy you 51.81 shares of stock.
就Tharimmune而言，截至發佈時的交易價格爲1.93美元，100美元將爲您購買51.81股股票。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果你想對一家公司下注，這個過程會更加複雜。您需要訪問期權交易平台或經紀商，該經紀人將允許您 「空頭」 一股股票，將股票借給您。可以在此資源中找到做空股票的過程。否則，如果您的經紀人允許您交易期權，您可以買入看跌期權，也可以以高於當前股票交易價格的行使價賣出看漲期權——無論哪種方式，它都允許您從股價下跌中獲利。
THAR Price Action: At the time of publication, Tharimmune shares were down 8.29% at $1.99, according to data from Benzinga Pro.
THAR價格走勢：根據Benzinga Pro的數據，在發佈時，Tharimmune股價下跌8.29％，至1.99美元。
Image: Photo by roberto-sorin for Unsplash
圖片：roberto-sorin 爲 Unsplash 拍攝的照片
